PubRank

J E Audia

Author PubWeight™ 14.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001 4.45
2 Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol 1993 1.07
3 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997 0.98
4 Species differences in the pharmacology of the 5-hydroxytryptamine2 receptor: structurally specific differentiation by ergolines and tryptamines. J Pharmacol Exp Ther 1993 0.91
5 N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-HT2 receptor. Eur J Pharmacol 1993 0.86
6 LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1. Proc Natl Acad Sci U S A 1993 0.81
7 Amyloid beta-mediated oxidative and metabolic stress in rat cortical neurons: no direct evidence for a role for H2O2 generation. J Neurochem 1996 0.80
8 Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation. Cephalalgia 2003 0.80
9 N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist. J Med Chem 1999 0.79
10 Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo. Prog Neuropsychopharmacol Biol Psychiatry 1995 0.78
11 N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy. J Med Chem 2001 0.78
12 Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells. J Steroid Biochem Mol Biol 1996 0.77
13 Nonsteroidal inhibitors of human type I steroid 5-alpha-reductase. J Med Chem 1993 0.76
14 LY191704 inhibits type I steroid 5 alpha-reductase in human scalp. J Clin Endocrinol Metab 1996 0.75
15 Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5alpha-reductase. J Steroid Biochem Mol Biol 2000 0.75
16 Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. Prostate Suppl 1996 0.75
17 Synthesis and 5 alpha-reductase inhibitory activity of 8-substituted benzo[f]quinolinones derived from palladium mediated coupling reactions. Bioorg Med Chem Lett 1998 0.75